title: Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts.
abstract: BACKGROUND
  A mutation in the cardiac sodium channel gene (SCN5A) has been described in patients with the syndrome of right bundle branch block, ST-segment elevation in leads V1 to V3, and sudden death (Brugada syndrome). These electrocardiographic manifestations are transient in many patients with the syndrome. The present study examined arrhythmic risk in patients with overt and concealed forms of the disease and the effectiveness of sodium channel blockers to unmask the syndrome and, thus, identify patients at risk.
  
  
  RESULTS
  The effect of intravenous ajmaline (1 mg/kg), procainamide (10 mg/kg), or flecainide (2 mg/kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a SCN5A mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C). Ajmaline, procainamide, or flecainide administration resulted in ST-segment elevation and right bundle branch block in all patients in group A and in all 11 patients with the mutation in group B. A similar pattern could not be elicited in the 8 patients in group B who lacked the mutation or in any person in group C. The follow-up period (37+/-33 months) revealed no differences in the incidence of arrhythmia between the 34 patients in whom the phenotypic manifestation of the syndrome was transient and the 24 patients in whom it was persistent (log-rank, 0.639).
  
  
  CONCLUSIONS
  The data demonstrated a similar incidence of potentially lethal arrhythmias in patients displaying transient versus persistent ST-segment elevation and right bundle branch block, as well as the effectiveness of sodium channel blockers to unmask the syndrome and, thus, identify patients at risk.
authors.affiliation: Department of Cardiology, Baylor College of Medicine, Houston, Texas, USA.
authors.forename: R
authors.initials: R
authors.lastname: Brugada
authors.forename: J
authors.initials: J
authors.lastname: Brugada
authors.forename: C
authors.initials: C
authors.lastname: Antzelevitch
authors.forename: G E
authors.initials: GE
authors.lastname: Kirsch
authors.forename: D
authors.initials: D
authors.lastname: Potenza
authors.forename: J A
authors.initials: JA
authors.lastname: Towbin
authors.forename: P
authors.initials: P
authors.lastname: Brugada
mesh_terms: D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D002037:Bundle-Branch Block / Q000150:complications* / Q000235:genetics; D016757:Death, Sudden, Cardiac / Q000209:etiology*; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D062554:NAV1.5 Voltage-Gated Sodium Channel; D010375:Pedigree; D012307:Risk Factors; D026941:Sodium Channel Blockers; D015222:Sodium Channels / Q000235:genetics
chemical_list: D000889:Anti-Arrhythmia Agents; D062554:NAV1.5 Voltage-Gated Sodium Channel; C568320:SCN5A protein, human; D026941:Sodium Channel Blockers; D015222:Sodium Channels